ID HBV Vaccination With Imiquimod in OBI
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03307902|
Recruitment Status : Recruiting
First Posted : October 12, 2017
Last Update Posted : October 12, 2017
During the course of chronic hepatitis B infection, patients may undergo hepatitis B surface antigen (HBsAg) seroclearance, resulting in undetectable circulating HBsAg. With the advance of sensitive nucleic acid detection techniques, HBsAg-negative subjects with detectable HBV DNA in sera or liver tissues can be identified. Patients who have undetectable HBsAg and yet detectable HBV DNA in sera or liver tissues are defined as having occult HBV infection (OBI). OBI as a cause of liver disease in HBsAg-negative patients remains clinically important [1,2]. Studies conducted by our research group had demonstrated that patients with HBsAg seroclearance could still develop flare of hepatitis B, advanced liver diseases and HCC [3-6]. Prevention of these complications in OBI patients by conventional intramuscular hepatitis B vaccination (HBVv) remains elusive with poor amnestic anti-HBs response .
The objective of this prospective double-blind randomized controlled trial is to evaluate the effect and safety of topical treatment with imiquimod immediately before intradermal vaccination with Sci-B-Vac™ in patients with OBI. Our a priori hypothesis is that imiquimod pretreatment would improve immune responses to Sci-B-Vac™ further in OBI patients, resulting in HBsAb conversion. Thereby preventing subsequent complications including flare of hepatitis, cirrhosis and HCC in these patients.
|Condition or disease||Intervention/treatment||Phase|
|Hepatitis B||Biological: Imiquimod + ID HBVv Biological: Aqueous + ID HBVv Biological: Imiquimod + IM HBVv||Phase 2 Phase 3|
This randomized double-blind placebo-controlled trial will compare the safety, immunogenicity and clinical efficacy of Sci-B-Vac™ with topical ointment pretreatment among 5 groups. Group 1: Intradermal Sci-B-Vac™ with topical imiquimod ointment pretreatment; Group 2: Intradermal Sci-B-Vac™ with topical aqueous cream (placebo) pretreatment; Group 3: Intramuscular Sci-B-Vac™ with topical imiquimod ointment pretreatment.
Vaccination Regimen and Data Collection Enrolled patients will be randomized into 3 groups after written informed consent. Each patient will receive a 3 doses Sci-B-Vac™ regime at 0, 1 and 6 months. Group 1 will receive a total of 10μg intradermal HBsAg each time with topical imiquimod ointment pretreatment; Group 2 will receive a total of 10μg intradermal HBsAg each time with topical aqueous cream pretreatment. Group 3 will receive a total of 10μg intramuscular HBsAg each time with topical imiquimod ointment pretreatment.
The primary outcome measurement will be the seroprotection rate of the HBVv at 12 months after the first dose of vaccination and the secondary outcome measurements will include the seroconversion rate, the GMT fold increase and the safety of the intradermal Sci-B-Vac™ with topical imiquimod treatment at other time points.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||70 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Masking Description:||Double blind|
|Official Title:||Intradermal Hepatitis B Vaccination With Imiquimod in Occult Hepatitis B Infection|
|Actual Study Start Date :||October 1, 2016|
|Estimated Primary Completion Date :||September 30, 2018|
|Estimated Study Completion Date :||December 30, 2018|
Experimental: Imiquimod + ID HBVv
topical imiquimod + intradermal hepatitis B vaccination
Biological: Imiquimod + ID HBVv
Imiquimod ointment + intradermal 10μg Sci-B-Vac vaccine
Active Comparator: Aqueous + ID HBVv
topical aqueous + intradermal hepatitis B vaccination
Biological: Aqueous + ID HBVv
Aqueous ointment + intradermal 10μg Sci-B-Vac vaccine
Active Comparator: Imiquimod + IM HBVv
topical imiquimod + intramuscular hepatitis B vaccination
Biological: Imiquimod + IM HBVv
Imiquimod ointment + intramuscular 10μg Sci-B-Vac vaccine
- Seroprotection rate to HBV at 12 month [ Time Frame: 12 month ]Percentage of recruited subjects with anti-HBs antibody titre >10mIU/mL
- Seroprotection rate to HBV at 1 month [ Time Frame: 1 month ]Percentage of recruited subjects with anti-HBs antibody titre >10mIU/mL
- Seroprotection rate to HBV at 6 month [ Time Frame: 6 month ]Percentage of recruited subjects with anti-HBs antibody titre >10mIU/mL
- GMT of anti-HBs at 1 month [ Time Frame: 1 month ]Geometric mean titre of anti-HBs antibody at 1 month after vaccination
- GMT of anti-HBs at 6 month [ Time Frame: 6 month ]Geometric mean titre of anti-HBs antibody at 6 month after vaccination
- GMT of anti-HBs at 12 month [ Time Frame: 12 month ]Geometric mean titre of anti-HBs antibody at 12 month after vaccination
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03307902
|Contact: Ivan Hung, MD FRCPfirstname.lastname@example.org|
|University of Hong Kong||Recruiting|
|Hong Kong, Hong Kong|
|Contact: Ivan Hung, MD FRCP 2255 4049 email@example.com|